- Home
- SAFE vs LQDA Comparison
SAFE vs LQDA Comparison
Compare SAFE & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAFE
- LQDA
- Stock Information
- Founded
- SAFE 2016
- LQDA 2004
- Country
- SAFE United States
- LQDA United States
- Employees
- SAFE N/A
- LQDA N/A
- Industry
- SAFE Real Estate Investment Trusts
- LQDA Biotechnology: Pharmaceutical Preparations
- Sector
- SAFE Real Estate
- LQDA Health Care
- Exchange
- SAFE Nasdaq
- LQDA Nasdaq
- Market Cap
- SAFE 1.1B
- LQDA 1.2B
- IPO Year
- SAFE 2017
- LQDA 2018
- Fundamental
- Price
- SAFE $14.71
- LQDA $19.60
- Analyst Decision
- SAFE Buy
- LQDA Strong Buy
- Analyst Count
- SAFE 9
- LQDA 9
- Target Price
- SAFE $22.33
- LQDA $27.67
- AVG Volume (30 Days)
- SAFE 397.2K
- LQDA 2.4M
- Earning Date
- SAFE 08-05-2025
- LQDA 08-06-2025
- Dividend Yield
- SAFE 4.80%
- LQDA N/A
- EPS Growth
- SAFE N/A
- LQDA N/A
- EPS
- SAFE 1.46
- LQDA N/A
- Revenue
- SAFE $391,206,000.00
- LQDA $14,144,000.00
- Revenue This Year
- SAFE $0.32
- LQDA $189.27
- Revenue Next Year
- SAFE $5.07
- LQDA $402.79
- P/E Ratio
- SAFE $10.09
- LQDA N/A
- Revenue Growth
- SAFE 2.64
- LQDA N/A
- 52 Week Low
- SAFE $13.68
- LQDA $8.26
- 52 Week High
- SAFE $28.80
- LQDA $19.76
- Technical
- Relative Strength Index (RSI)
- SAFE 41.10
- LQDA 79.39
- Support Level
- SAFE $14.65
- LQDA $14.04
- Resistance Level
- SAFE $15.43
- LQDA $14.67
- Average True Range (ATR)
- SAFE 0.41
- LQDA 0.89
- MACD
- SAFE -0.05
- LQDA 0.70
- Stochastic Oscillator
- SAFE 8.63
- LQDA 97.88
About SAFE Safehold Inc. New
Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.